Clinical Report: Insomnia Outcomes May Vary by Measurement Method
Overview
Revise to emphasize the importance of capturing daytime symptoms in treatment assessments.
Background
Insomnia affects a significant portion of the adult population, leading to diminished quality of life and various health complications. Accurate assessment of insomnia treatment outcomes is crucial for effective management, particularly as insomnia often co-occurs with other psychiatric disorders. The reliance on standard patient-reported outcomes may obscure important daytime effects of insomnia therapies.
Data Highlights
Measurement Method
Findings
Standard Questionnaires
Reduced insomnia severity; no significant differences in daytime fatigue, mood, or cognition
EMA
Greater morning fatigue and reduced alert cognition; lower fatigue and sleepiness later in the day
Key Findings
EMA detected significant time-of-day-specific treatment effects of suvorexant.
Standard questionnaires showed reduced insomnia severity but missed daytime symptom changes.
Participants reported greater morning fatigue and reduced cognition earlier in the day with suvorexant.
High completion rates of EMA indicate its feasibility in older adults.
Reliance on retrospective measures may obscure clinically relevant daytime effects.
Clinical Implications
Clinicians should consider integrating EMA into routine assessments of insomnia treatments to capture nuanced daytime symptoms. This approach may enhance the understanding of treatment impacts and support more informed clinical decisions regarding ongoing medication use.
Conclusion
The findings highlight the importance of refining outcome measurement in insomnia research and clinical practice, advocating for broader adoption of EMA to improve patient-centered treatment decisions.
